On Friday, Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY) for $825 million as an upfront payment and additional commercial milestone payments of up to $250 million.
Enjaymo, a humanized monoclonal antibody, is the only approved targeted product for cold agglutinin disease (CAD), a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis).
Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease.
The FDA approved the drug in 2022. Administered as chronic IV treatment.
Enjaymo ...
